Is Alphabet finally ready to cut ties with Verily after a decade of costly health care moonshots?

Alphabet Inc. (NASDAQ: GOOGL) is preparing to shed its life sciences subsidiary Verily, either through a sale or a corporate spinoff, according to reporting by Bloomberg, which cited testimony from a senior Google executive during ongoing U.S. antitrust proceedings. The move marks a decisive step in Alphabet’s years-long process of restructuring its portfolio of “Other Bets” and signals a broader trend of Big Tech recalibrating its exposure to health care and life sciences.

During testimony in the U.S. Department of Justice case that accuses Google of monopolizing advertising technology, Heather Adkins, Google’s vice president of security engineering, disclosed that Alphabet has spent more than two years disentangling Verily’s systems from Google’s proprietary infrastructure. She explained that the effort was designed to prepare Verily to operate independently, shifting from Alphabet’s internal systems to Google Cloud and other commercially available platforms. According to the Bloomberg report, Adkins said this process was intended to position Verily to “no longer be an Alphabet entity.”

The disclosure underscores how Alphabet is moving Verily toward full autonomy after years of shared reliance on its parent’s technology. While Alphabet has not issued a public statement detailing whether it prefers a sale or spinoff, Bloomberg noted that the signals from executives strongly suggest Verily is being readied for independence.

How has Verily positioned itself for independence through restructuring and asset divestments?

Founded in 2015 as one of Alphabet’s most ambitious “moonshot” projects, Verily was conceived to apply Google’s engineering and data science expertise to some of the hardest problems in health care. The vision was sweeping: integrate advanced sensors, machine learning, and large-scale data analytics to transform the way diseases are detected, clinical trials are managed, and populations are monitored. Verily quickly drew attention for its breadth of experimentation, from partnerships with Johnson & Johnson on surgical robotics to ventures with Novartis and Dexcom in diabetes management. Yet as the years went by, it became increasingly clear that the diversity of Verily’s projects—ranging from digital biomarkers and biosensors to population-level disease mapping—created both operational sprawl and a heavy financial burden. For Alphabet shareholders, the unit became emblematic of the tension between Silicon Valley ambition and health care’s slow, regulation-heavy realities.

By early 2025, that tension had boiled into a restructuring imperative. One of the most notable moves came with the sale of Granular, Verily’s health insurance subsidiary, to Elevance Health. According to Bloomberg and other financial media, the decision was designed to simplify Verily’s business model and reduce exposure to capital-intensive lines of business. Granular had been launched with the goal of combining personalized data and insurance design, but operating an insurance provider placed Verily in direct competition with legacy insurers, demanding compliance and capital reserves that weighed heavily on Alphabet’s balance sheet. The divestiture sent a clear signal: Verily was pulling back from high-cost adjacencies and pivoting toward scalable digital platforms.

Around the same time, Verily announced the closure of its medical devices division. This unit had attracted significant attention in its early days, particularly for the much-hyped glucose-monitoring contact lens project. While groundbreaking in concept, the device proved commercially unviable, underscoring the gap between laboratory innovation and regulatory approval in health care hardware. Shuttering the division eliminated one of Verily’s most resource-intensive endeavors and reinforced its intention to focus on areas where software, data, and AI can deliver faster returns.

These portfolio decisions were followed by targeted workforce reductions and operational realignments. Staff cuts in late 2024 and early 2025 were positioned as necessary to contain costs, but they also reflected a strategic narrowing of scope. Instead of spreading resources thinly across dozens of high-risk experiments, Verily began doubling down on its core competencies in health data integration, clinical trial management, and AI-driven patient monitoring. In an industry increasingly shaped by data infrastructure and predictive analytics, these areas give Verily a clearer competitive identity.

Analysts and investors have described this restructuring as essential groundwork for independence. By offloading noncore assets and narrowing its operational footprint, Verily has become a cleaner story for potential backers. External investors—whether strategic health care players, private equity funds, or public markets—tend to favor companies with a focused mission, scalable technology, and predictable revenue models. While Verily is still seen as an early-stage business compared with Alphabet’s cash-generating units, the restructuring has positioned it as a more credible candidate for a standalone trajectory.

In short, the Verily of 2025 is a leaner, more disciplined entity than the sprawling “moonshot” of 2015. Its reduced risk profile, sharpened focus on AI and data-driven health care, and readiness for external capital all point toward a future where it could operate as a viable independent health technology company—whether as a spinoff retaining Alphabet’s backing or as part of a sale to a larger industry player.

What does this decision reveal about Alphabet’s shifting strategy for its “Other Bets” portfolio?

Alphabet’s “Other Bets” have long been a source of fascination for analysts but also a frequent source of financial drag. Waymo, Calico, and Verily are emblematic of Alphabet’s willingness to invest in ambitious, long-horizon ideas. Yet this segment has consistently posted operating losses running into billions of dollars annually.

According to Bloomberg’s reporting, Alphabet’s decision to ready Verily for independence comes at a time when regulators are pressing the company to make structural changes in its core advertising business. The DOJ case against Google has centered on allegations of anticompetitive conduct in ad tech. Alphabet has argued that divestitures in this space would be harmful and technically challenging. By voluntarily spinning off or selling Verily, Alphabet can show both regulators and investors that it is willing to restructure on its own terms, outside of forced remedies in its core business.

How could a Verily spinoff reshape the health technology and life sciences landscape?

If Verily exits Alphabet’s umbrella, the health technology sector could see a new standalone competitor. Verily is already known for its expertise in health data and clinical research platforms. Independence would allow the company to raise funds externally, pursue partnerships more aggressively, and potentially enter public markets.

The health technology space has grown increasingly competitive, with players such as Amazon, Apple, and Microsoft expanding into health care alongside traditional firms like Siemens Healthineers and Johnson & Johnson. Bloomberg noted that Verily’s independence could make it more nimble in competing for contracts and collaborations, particularly in clinical trial infrastructure and digital health analytics.

However, independence also introduces risk. Without Alphabet’s financial backing, Verily must prove it can reach profitability while navigating regulatory complexities in health care. Investors may demand a clearer roadmap to sustainable revenues before valuing Verily at levels comparable to other listed digital health firms.

What does this mean for Alphabet shareholders and institutional sentiment toward Big Tech restructuring?

For Alphabet shareholders, a Verily separation could be viewed positively if it reduces ongoing operating losses in the “Other Bets” portfolio. Analysts have often urged Alphabet to sharpen its focus on core engines like advertising, YouTube, Google Cloud, and artificial intelligence. A divestment could also unlock hidden value by providing transparency into Verily’s standalone financials.

Institutional sentiment has generally supported efforts by Big Tech firms to streamline noncore businesses. Bloomberg’s report suggests that Alphabet’s readiness to offload Verily may be interpreted as a proactive move to align capital allocation with shareholder priorities. Yet investors will remain cautious about Verily’s ability to thrive without Alphabet’s deep pockets.

Will Alphabet’s decision to spin off Verily truly unlock lasting value for shareholders and reshape the future of health technology innovation?

Bloomberg’s disclosure of Alphabet’s plan to sell or spin off Verily highlights a turning point in the evolution of the search giant’s diversification strategy. It reflects not only the practical limits of sustaining moonshot projects under Alphabet’s umbrella but also the company’s desire to show flexibility in an era of mounting regulatory and investor pressure.

For Alphabet, the divestiture of Verily would tighten its focus on high-margin businesses while still allowing it to retain a stake in health care innovation. For Verily, the path ahead is more uncertain: independence provides new opportunities for investment and partnerships but removes the safety net of Alphabet’s backing.

The success or failure of this move will be closely watched by both Wall Street and Silicon Valley. If Verily flourishes as an independent health technology company, it may validate Alphabet’s restructuring playbook and encourage other tech giants to reconsider their own diversification strategies. If it falters, the risks of translating ambitious health innovation into sustainable businesses will once again come into focus.

Either way, Alphabet’s reported plan, as revealed by Bloomberg, is a reminder that even the biggest technology companies cannot escape the trade-offs between ambition, profitability, and regulatory scrutiny.